ADC Therapeutics SA — Form 6-K Summary
Filing date: February 28, 2023. Reporting period: fourth quarter and fiscal year ended December 31, 2022. The filing reports results and business updates for the Swiss commercial-stage biotechnology company.
Business Context and Key Developments
- ZYNLONTA (loncastuximab tesirine-lpyl) is approved in the United States for certain relapsed or refractory large B-cell lymphomas. Conditional marketing authorizations were also granted in Europe and the United Kingdom for third-line DLBCL.
- ADC Therapeutics entered into a collaboration and clinical supply agreement with Roche to evaluate ZYNLONTA in combination therapies in the Phase 1 LOTIS-7 trial.
- Cami (camidanlumab tesirine) is being advanced through a potential partnering strategy following positive Phase 2 data.
- Pipeline programs include ADCT-901, ADCT-601, ADCT-602, ADCT-212 and ADCT-701, with multiple clinical data or trial-initiation milestones expected during 2023 and 2024.
Financial Results
| Metric | Q4 2022 | Q4 2021 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Net product revenue | $19.8 million | $17.0 million | $74.9 million | $33.9 million |
| License revenue | $50.0 million | None reported | $135.0 million | None reported |
| Total revenue | $69.8 million | $17.0 million | $209.9 million | $33.9 million |
| Operating expenses | $80.5 million | $79.8 million | $333.5 million | $295.6 million |
| Loss from operations | $10.7 million | $62.8 million | $123.6 million | $261.7 million |
| Net loss | $24.2 million | $34.4 million | $155.8 million | $230.0 million |
| Adjusted net loss | $7.9 million | $30.0 million | $81.7 million | $186.1 million |
| Net loss per share | $0.30 | $0.45 | $1.99 | $3.00 |
Q4 ZYNLONTA net sales increased 16.5% year over year but declined 7.0% sequentially from Q3, primarily because of higher gross-to-net deductions and fluctuations in individual ordering accounts. Full-year product revenue increased 120.9%, reflecting a full year of U.S. commercial activity in 2022 versus a partial year in 2021.
R&D expense increased to $187.9 million for 2022 from $158.0 million, reflecting continued pipeline investment. Full-year selling and marketing expense rose to $69.1 million from $64.8 million, while G&A expense was broadly stable at $72.0 million versus $71.5 million. Cost of product sales included a $2.5 million impairment charge for out-of-specification product intermediates and antibodies; the company stated that supply capability was not affected.
Cash, Debt and Liquidity
- Cash and cash equivalents were $326.4 million at December 31, 2022, compared with $466.5 million at December 31, 2021 and $380.9 million at September 30, 2022.
- The balance at December 31 excluded a $50.0 million Sobi milestone received in February 2023 and an expected $75.0 million HealthCare Royalty Partners milestone triggered by the first European commercial sale.
- Management expects the cash runway to extend into the middle of 2025 based on its business plan and the expected milestone.
- Senior secured term loans totaled $109.7 million, including $12.5 million classified as current and $97.2 million as long-term. The balance sheet also included a $212.4 million long-term deferred royalty obligation and $1.8 million of warrant obligations.
- Cash flow statements and a clear operating cash-burn figure are not provided in the filing text.
Outlook, Guidance and Risks
- Expected milestones include a European phased ZYNLONTA launch by Sobi in the second quarter of 2023, LOTIS-5 enrollment completion in 2024, and preliminary LOTIS-7 and LOTIS-9 data in 2024.
- ADCT-901 and ADCT-601 preliminary data are expected in the first half of 2024; ADCT-212 is expected to enter Phase 1 in the first half of 2024; ADCT-602 expansion is expected to complete in the first half of 2024; and ADCT-701 is expected to enter Phase 1 in the second half of 2023.
- The filing references 2023 net product sales guidance and an expected reduction in total operating expenses in 2023 and 2024, but the supplied filing text does not provide the numerical guidance values.
- Key risks include commercial uptake and reimbursement of ZYNLONTA, Sobi’s European launch execution, regulatory approval and clinical-trial outcomes, dependence on partners, substantial indebtedness and debt-service requirements, future financing needs, and the ability to maintain the projected cash runway.
- ZYNLONTA’s U.S. approval was granted under the FDA accelerated-approval pathway; continued approval may depend on verification and description of clinical benefit in a confirmatory trial.
Important Investor Verification Items
- Verify the numerical 2023 ZYNLONTA sales and operating-expense guidance, which is not stated in the supplied text.
- Confirm receipt and conditions of the $50.0 million Sobi milestone and the timing and terms of the expected $75.0 million royalty-partner milestone.
- Review debt covenants, repayment schedules, restrictions and cash-service requirements under the senior secured facilities and royalty arrangement.
- Assess the sustainability of ZYNLONTA demand, gross-to-net deductions, reimbursement and Sobi’s European commercialization.
- Track confirmatory and combination-trial results, particularly those relevant to the accelerated U.S. approval and the LOTIS programs.
- Reconcile adjusted net loss to IFRS net loss; adjusted results exclude recurring share-based compensation and other financing, derivative and royalty-related items.